IT1271684B - Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi - Google Patents

Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi

Info

Publication number
IT1271684B
IT1271684B ITMI941560A ITMI941560A IT1271684B IT 1271684 B IT1271684 B IT 1271684B IT MI941560 A ITMI941560 A IT MI941560A IT MI941560 A ITMI941560 A IT MI941560A IT 1271684 B IT1271684 B IT 1271684B
Authority
IT
Italy
Prior art keywords
urokinase receptor
antisense oligonucleotides
messenger rna
human urokinase
oligonucleotides complementary
Prior art date
Application number
ITMI941560A
Other languages
English (en)
Inventor
Sergio Capaccioli
Rosso Mario Del
Gabriella Fibbi
Alessandro Quattrone
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Publication of ITMI941560A0 publication Critical patent/ITMI941560A0/it
Priority to ITMI941560A priority Critical patent/IT1271684B/it
Priority to US08/776,062 priority patent/US5872106A/en
Priority to DE69512522T priority patent/DE69512522T2/de
Priority to EP95926907A priority patent/EP0772620B1/en
Priority to AT95926907T priority patent/ATE185144T1/de
Priority to ES95926907T priority patent/ES2136868T3/es
Priority to DK95926907T priority patent/DK0772620T3/da
Priority to PCT/EP1995/002793 priority patent/WO1996003414A1/en
Priority to JP50542496A priority patent/JP3687919B2/ja
Priority to AU31123/95A priority patent/AU3112395A/en
Publication of ITMI941560A1 publication Critical patent/ITMI941560A1/it
Application granted granted Critical
Publication of IT1271684B publication Critical patent/IT1271684B/it
Priority to GR990403078T priority patent/GR3031985T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Oligonucleotidi antisenso - fosfodiesteri eventualmente stabilizzati con residui fosforotioati o analoghi, oppure modificati nell'intero scheletro zucchero - fosfato - di sequenza complementare all'RNA messaggero del recettore umano dell'urochinasi sono in grado di abolire l'invasività di cellule neoplastiche inibendo la superespressione del recettore stesso, diretto responsabile del fenotipo invasivo. Tali oligomeri possono pertanto essere impiegati come medicamenti per il trattamento di neoplasie primarie e secondarie, nonché in altre forme patologiche nelle quali la superespressione del recettore dell'urochinasi è evento patogenico.
ITMI941560A 1994-07-22 1994-07-22 Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi IT1271684B (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ITMI941560A IT1271684B (it) 1994-07-22 1994-07-22 Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi
DK95926907T DK0772620T3 (da) 1994-07-22 1995-07-17 Anti-messenger-oligonucleotider og urokinase-recepter-reversion af den invasive fænotype af transformerede humane fibroblas
DE69512522T DE69512522T2 (de) 1994-07-22 1995-07-17 Antimessenger oligonukleotide und urokinaserezeptor umkehrung des invasive phänotyps transformieter menschlicher fibroblasten durch antimessenger oligonukleotidinhibierung von urokinaserezeptoren-expression
EP95926907A EP0772620B1 (en) 1994-07-22 1995-07-17 Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression
AT95926907T ATE185144T1 (de) 1994-07-22 1995-07-17 Antimessenger oligonukleotide und urokinaserezeptor umkehrung des invasive phänotyps transformieter menschlicher fibroblasten durch antimessenger oligonukleotidinhibierung von urokinaserezeptoren-expression
ES95926907T ES2136868T3 (es) 1994-07-22 1995-07-17 Oligonucleotidos antimensajeros y reversion del receptor de uroquinasa del fenotipo invasivo de fibroplastos humanos transformados mediante inhibicion del oligonucleotido antimensajero del gen exp del recptor de uroquinasa.
US08/776,062 US5872106A (en) 1994-07-22 1995-07-17 Antimessenger oligonucleotide against urokinase receptor
PCT/EP1995/002793 WO1996003414A1 (en) 1994-07-22 1995-07-17 Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression
JP50542496A JP3687919B2 (ja) 1994-07-22 1995-07-17 アンチメッセンジャー・オリゴヌクレオチド、およびウロキナーゼ受容体遺伝子発現のアンチメッセンジャー・オリゴヌクレオチド阻害による形質転換されたヒト繊維芽細胞の浸潤性表現型のウロキナーゼ受容体復帰変異
AU31123/95A AU3112395A (en) 1994-07-22 1995-07-17 Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression
GR990403078T GR3031985T3 (en) 1994-07-22 1999-11-29 Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI941560A IT1271684B (it) 1994-07-22 1994-07-22 Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi

Publications (3)

Publication Number Publication Date
ITMI941560A0 ITMI941560A0 (it) 1994-07-22
ITMI941560A1 ITMI941560A1 (it) 1996-01-22
IT1271684B true IT1271684B (it) 1997-06-04

Family

ID=11369344

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI941560A IT1271684B (it) 1994-07-22 1994-07-22 Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi

Country Status (11)

Country Link
US (1) US5872106A (it)
EP (1) EP0772620B1 (it)
JP (1) JP3687919B2 (it)
AT (1) ATE185144T1 (it)
AU (1) AU3112395A (it)
DE (1) DE69512522T2 (it)
DK (1) DK0772620T3 (it)
ES (1) ES2136868T3 (it)
GR (1) GR3031985T3 (it)
IT (1) IT1271684B (it)
WO (1) WO1996003414A1 (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
AU2197600A (en) * 1998-12-30 2000-07-24 Oligos Etc. Inc. Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
WO2005016374A1 (en) * 2003-07-02 2005-02-24 Board Of Regents, The University Of Texas System Regulation of urokinase receptor expression by phosphoglycerate kinase
WO2017043490A1 (ja) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 自然免疫誘導効果が増強した二重鎖リボ核酸

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1013285A3 (en) * 1989-04-07 2004-05-19 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Urokinase-type plasminogen activator receptor

Also Published As

Publication number Publication date
DE69512522D1 (de) 1999-11-04
ATE185144T1 (de) 1999-10-15
DE69512522T2 (de) 2000-01-13
US5872106A (en) 1999-02-16
EP0772620A1 (en) 1997-05-14
AU3112395A (en) 1996-02-22
JP3687919B2 (ja) 2005-08-24
GR3031985T3 (en) 2000-03-31
ITMI941560A1 (it) 1996-01-22
ITMI941560A0 (it) 1994-07-22
EP0772620B1 (en) 1999-09-29
WO1996003414A1 (en) 1996-02-08
JPH10502823A (ja) 1998-03-17
ES2136868T3 (es) 1999-12-01
DK0772620T3 (da) 2000-03-27

Similar Documents

Publication Publication Date Title
GR3024597T3 (en) 7-deazapurine modified oligonucleotides
ATE216705T1 (de) Antisense-oligonukleotidmodulation der raf- genexpression
WO1996019568A3 (en) Stabilized ribozyme analogs
ATE213019T1 (de) Chimäre oligomere mit einer rns- spaltungsaktivität
CA2303848A1 (en) Substituted anilides
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
DK0788366T3 (da) Anvendelse af 2'-substituerede oligonucleotider til regulering af genekspression
EP1325019A4 (en) ANTISENSE MODULATION OF CLUSTERINEXPRESSION
ATE174599T1 (de) Bindungskompetente oligomere, die 2',5'-bindungen enthalten
FR2804960B1 (fr) Nouveaux oligonucleotides et utilisation d'oligonucleotides modulant l'expression de la tyrosinase et de la tyrosinase- related-protein 1 comme agents depigmentants
PH22819A (en) Ultra mild skin cleansing composition
CA2345354A1 (en) Antisense modulation of bcl-x expression
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
NO20002702L (no) Tienopyrimidiner
EP1131107A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INHIBITOR-KAPPA-B-KINASE-ALPHA
HK1054409A1 (zh) 鞘氨醇激酶及其應用
MX9800622A (es) Agentes terapeuticos mejorados.
BRPI0012553B8 (pt) pastilha contendo cloridrato de ambroxol, seu processo de preparação e seu uso
EP1163373A4 (en) ANTISENSE MODULATION OF THE CELLULAR INHIBITANT OF THE APOPTOSIS EXPRESSION
MX9800049A (es) Antraquinonas mono- y disulfo-substituidas y su uso para el tratamiento de trastornos de la matriz del hueso.
DE69434809D1 (de) Bc200 rna, daraus abgeleitete proben und entsprechende anwendungen
GR3031985T3 (en) Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression
BR9804983A (pt) Processos de depuração de 1,1-difluoroetano em cloreto de vinila e de produção de 1,1-difluoroetano, e, 1-1-difluoroetano.
IL161181A0 (en) Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
HUP9802142A2 (hu) Na+/H+ -ioncsere inhibítorok alkalmazása a központi idegrendszer betegségeinek kezelésére és megelőzésére alkalmas gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970729